drugset
drugset / Trial / NCT04478071

Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

NCT04478071 ↗

Phase 2 Completed 448 enrolled The University of Texas Health Science Center, Houston Akebia Therapeutics · collabUnited States Department of Defense · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of vadadustat for the prevention and treatment of acute respiratory distress syndrome (ARDS) in hospitalized patients with Coronavirus Disease 2019 (COVID-19).

Timeline

Start
2020-08-22
Primary completion
2022-03-07
Completion
2022-03-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Vadadustat Small molecule — —

Indications

COVID-19 acute respiratory distress syndrome